Background: Serologic assays that identify herpes simplex type 2 (HSV-2) type-specific antibodies have been commercially available for more than a decade. Greater acceptance of these tests is hindered by uncertainty regarding their performance in real-world clinical settings.
Objectives: The primary objective was to compare the test characteristics of the Focus HerpeSelect Express Assay (EA) versus the Focus HerpeSelect enzyme linked immunoassay (ELISA) for detection of HSV-2 type-specific antibodies among pregnant women enrolled from 3 geographic sites with varying prevalences of HSV-2 infection. A second objective was to evaluate the performance of a HSV-2 testing strategy in which EA screens and ELISA confirms HSV-2 serodiagnosis.
Study Design: We enrolled 399 pregnant women from Atlanta, GA, Moorestown, NJ, and Pittsburgh, PA into this cross-sectional investigation. Capillary whole blood was obtained from study participants, and evaluated for the presence of type-specific HSV-2 antibodies using the EA. Serum samples were also obtained from all study participants for subsequent identification of HSV-2 type-specific antibodies using both ELISA and the Focus Immunoblot assays.
Results: We observed 96.2% agreement between results obtained with EA and ELISA. Overall, when compared to ELISA results, the sensitivity of EA for detection of HSV-2 type-specific antibodies was 94.2% and the specificity was 97.1%. Using Immunoblot results as our standard for performance calculations, the positive predictive value (PPV) of HSV-2 serodiagnosis increased from 91.7% to 98.2% when ELISA was used to confirm EA testing.
Conclusions: EA provides similar results to ELISA for the identification of HSV-2 type-specific antibodies among pregnant women. As use of the point-of-care (POC) EA in conjunction with confirmatory ELISA testing improves the PPV of HSV-2 serodiagnosis compared to the use of EA or ELISA testing alone, validation of this diagnostic algorithm in other at-risk populations may be warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716794 | PMC |
| http://dx.doi.org/10.1016/j.jcv.2008.11.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genital Herpes: Rapid Evidence Review.
Am Fam Physician
November 2024
Eglin Air Force Base Family Medicine Residency Program in Florida.
Article Synopsis
- - Genital herpes, caused by herpes simplex virus (HSV) types 1 or 2, is a lifelong sexually transmitted infection affecting over 500 million people globally, with no available vaccines for prevention.
- - It is characterized by painful genital lesions and flu-like symptoms; diagnosis is typically made through laboratory tests like PCR or viral culture.
- - Treatment includes antiviral medications to manage outbreaks and reduce transmission, and pregnant individuals with a history of genital herpes are advised to start antiviral therapy at 36 weeks and may require a cesarean section if lesions are present.
Human Antibodies against Herpes Simplex Virus 2 Glycoprotein G Do Not Neutralize but Mediate Antibody-Dependent Cellular Cytotoxicity.
Antibodies (Basel)
May 2024
Department of Infectious Diseases, Institute of Biomedicine, 413 90 Gothenburg, Sweden.
Herpes simplex virus 2 (HSV-2) is a sexually transmitted infection affecting 491 million individuals globally. Consequently, there is a great need for both prophylactic and therapeutic vaccines. Unfortunately, several vaccine clinical trials, primarily employing the glycoprotein D of HSV-2 (gD-2), have failed.
View Article and Find Full Text PDFAn unusual co-reactivation of herpes genitalis and shingles in a young male with primary genital herpes in partner.
Int J STD AIDS
May 2024
Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, India.
Background: Herpes simplex virus type 2 (HSV-2) is the most common cause of genital ulcers in industrialized countries. Herpes zoster (HZ) is an acute, cutaneous viral infection caused by the reactivation of the varicella-zoster virus (VZV).
Case Summary: A 27-year-old male presented with painful vesicles over the trunk for the last 5 days with painful genital erosions for the last 2 days.
HSV-2 infection and HPV incidence, persistence, and precancerous lesions in a cohort of HPV-vaccinated women living with HIV.
Int J STD AIDS
May 2023
Obstetrics & Gynecology, University of British Columbia, Vancouver, BC, CA.
Background: Several co-factors for HPV oncogenesis have been proposed, including co-infection with HSV-2. We assessed the relationship between HSV-2 infection and HPV-related outcomes in quadrivalent HPV-vaccinated (qHPV) women living with HIV (WLWH).
Methods: In this multi-site study of immunogenicity and efficacy of the qHPV vaccine in WLWH, visits took place at months -3, 0, 2, 6, 12, 18, 24, and annually thereafter.
Prevalence of herpes simplex virus 2 among MSM in Mainland China: a systematic review and meta-synthesis.
AIDS Res Ther
October 2022
Center for Disease Control and Prevention of Shangcheng District, Hangzhou, Zhejiang, China.
Background: As one of the most prolific sexually transmitted infections (STIs) in the world, Herpes Simplex Virus Type 2 (HSV-2) is one of the primary causes of genital ulcers. In addition, HSV-2 infection multiplies the risk of acquiring HIV. Men who have sex with men (MSM) are at particularly high risk of contracting both diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!